Why insider trading matters?

If management teams do not own any relevant stakes in the companies they guide, they may not be focused on creating wealth for shareholders to the same degree, compared to those that see their personal wealth increase when share prices rise.

- Klaus Gugler, Economist
SpringWorks Therapeutics, Inc. (SWTX)
Sector: Healthcare; Industry: Biotechnology

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas; Nirogacestat + belantamab mafodotin, which is in Phase Ib clinical trial for the treatment of relapsed or refractory multiple myeloma (RRMM); and Nirogacestat + ALLO-715 that is in preclinical trials for the treatment of RRMM. SpringWorks Therapeutics, Inc. has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib, as well as medicines; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2021-07-20 Islam Saqib Chief Executive Officer Sell 62,500 $76.56 $4,785,189 No
2021-07-01 ORBIMED ADVISORS LLC 10%-Owner Sell 15,959 $85.01 $1,356,675 No
2021-06-28 ORBIMED ADVISORS LLC 10%-Owner Sell 6,502 $85.17 $553,775 No
2021-06-25 ORBIMED ADVISORS LLC 10%-Owner Sell 56,634 $85.19 $4,824,541 No
2021-06-10 ORBIMED ADVISORS LLC 10%-Owner Sell 30,852 $85.09 $2,625,197 No
2021-06-09 ORBIMED ADVISORS LLC 10%-Owner Sell 48,053 $85.36 $4,101,908 No
2021-04-28 SQUINTO STEPHEN P 10%-Owner, Director Sell 19,432 $76.19 $1,480,522 No
2021-04-20 Islam Saqib Chief Executive Officer Sell 62,500 $68.02 $4,251,106 No
2021-04-15 SQUINTO STEPHEN P 10%-Owner, Director Sell 1,568 $75.04 $117,655 No
2021-04-13 Smith L. Mary Chief Development Officer Sell 10,000 $68.07 $680,723 Yes
2021-03-09 Bain Capital Life Sciences Investors, LLC 10%-Owner Sell 1,450,000 $71.50 $103,675,000 No
2021-03-01 ORBIMED ADVISORS LLC 10%-Owner Sell 1,220,000 $83.19 $101,491,800 No
2021-01-25 Edris Badreddin Chief Operating Officer Sell 32,000 $84.07 $2,690,282 No
2021-01-20 Smith L. Mary Chief Development Officer Sell 10,000 $78.70 $787,016 Yes
2021-01-20 Islam Saqib Chief Executive Officer Sell 62,500 $78.55 $4,909,390 No
2019-09-17 Lewis-Hall Freda C 10%-Owner, Director Buy 50,000 $18.00 $900,000 Yes
2019-09-17 SQUINTO STEPHEN P 10%-Owner, Director Buy 275,000 $18.00 $4,950,000 Yes
2019-09-17 ORBIMED ADVISORS LLC 10%-Owner Buy 275,000 $18.00 $4,950,000 Yes
2019-09-17 Bain Capital Life Sciences Investors, LLC 10%-Owner Buy 150,000 $18.00 $2,700,000 Yes
2019-09-17 PFIZER INC 10%-Owner Buy 50,000 $18.00 $900,000 Yes

Insider Smart

Mohawk Group Holdings, Inc. (MWK) - Multiple insiders bought MWK in June around $5, stock moved sideways for a month then made a 60% jump in 10 days. Patience is the key.

Insider Smart

Celldex Therapeutics, Inc. (CLDX) - Multiple insiders including President, EVP, CEO, CSO and Directors bought shares on Jun.9th, first time since 2018, this was very convincing and we initiated a position. Stock soared from $3 to 9$ in 2 days, and the run is still going on.